Biomarkers for increased risk of drug-induced acute hypersensitivity syndrome

Abstract

The present disclosure provides a method for predicting the risk of a patient for developing adverse drug reactions, particularly drug-induced acute hypersensitivity syndrome (AHSS). The disclosure also provides a method of identifying a subject afflicted with, or at risk of, developing AHSS. In some aspects, the methods comprise analyzing at least one genetic marker, wherein the presence of the at least one genetic marker indicates that the subject is afflicted with, or at risk of, developing AHSS.

Dependencies are inferred from the claim text.